Gemini Bio
Private Company
Total funding raised: $12M
Overview
GeminiBio is a long-established, private company that serves as a critical supplier to the biotech and cell therapy industry. Its core business is divided into two verticals: Cell Culture Solutions, including its flagship Human AB Serum and various fetal bovine sera, and Process Liquid Solutions, centered on its GemPure™ line of high-purity water. The company's value proposition lies in providing essential, quality-controlled raw materials and custom formulations that streamline and de-risk the complex manufacturing processes for advanced therapies. With dedicated, segregated manufacturing facilities for animal-origin-free and animal-component products, GeminiBio is positioned as a specialized partner for scaling from bench to commercial launch (BLA).
Technology Platform
Specialized manufacturing platform for biological sera (Human AB, FBS) and high-purity process liquids (WFI-quality water, custom buffers/media). Features segregated cGMP facilities (animal-origin-free and animal-component), aseptic assurance systems, and compliance with pharmacopeial standards (USP/EP/JP).
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Competes with large, integrated life science tools companies (e.g., Thermo Fisher Scientific, Merck KGaA, Sartorius) that offer broad portfolios of cell culture media and bioprocessing supplies. Also faces competition from other specialized serum and media suppliers (e.g., Cytiva, Bio-Techne, Seracare). Differentiation is achieved through deep specialization in Human AB Serum, segregated manufacturing facilities, and a strong focus on custom, GMP-grade solutions for cell therapy.